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years, was 95.1% in the case of GCSF+plerixafor therapy compared to 42.61% for 
GCSF. Additionally, the average reported cost for GCSF+plerixafor treatment in suc-
cessful cases was $35,020, and in the case of a GCSF treatment the cost totaled 
US$93,325, which represents a 62% saving for an actual year of therapy. Therefore, 
the GCSF+Plerixafor treatment results in a more effective, less costly, and ﬁnally the 
most viable alternative. CONCLUSIONS: The GCSF+Plerixafor treatment is a cost 
effective alternative, from a Mexican institutional perspective for Non Hodgkin’s 
Lymphoma patients in preparation for an autologous hematopoietic stem cell 
transplantation.
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COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK 
REDUCTION THERAPY: COMPARING TAMOXIFEN AND RALOXIFENE
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OBJECTIVES: To illustrate the relative value of raloxifene compared to tamoxifen, 
in the chemoprevention of invasive breast cancer in postmenopausal women in the 
United States. METHODS: Using outcomes data from the NSABP P-2 trial, a back-
ward induction model was performed from the societal perspective, comparing tamox-
ifen and raloxifene in postmenopausal women aged 35 to 80 years, with base case 
5-year breast cancer risk of 4.03%. Secondary outcomes considered were thrombo-
embolic events, cataracts, uterine hyperplasia and hysterectomy. Quality adjusted life 
years (QALY) gained from using raloxifene versus tamoxifen was estimated by con-
sidering the quality adjusted life expectancies for all model outcomes for each drug. 
Costs were in 2009 US dollars and costs and outcomes were discounted at an annual 
rate of 3%. An incremental cost effectiveness ratio (ICER) decision threshold of 
US$150000/QALY gained was used to determine age-cohort speciﬁc cost-effective-
ness. One-way sensitivity analyses were performed on outcome parameters and the 
discount rate, and threshold analyses were performed on parameters the model was 
sensitive to. RESULTS: Raloxifene was found to be cost effective relative to tamoxifen 
for all age-cohorts in the model, with ICERs between US$25,631 and US$30,133/
QALY gained at age 60 and 35 respectively. The model was most sensitive to raloxi-
fene cost, the ICER varying by +/-26.5% when the cost varied by +/-25%. The model 
was also sensitive to the probability of developing cataracts and requiring a hysterec-
tomy when on tamoxifen therapy. For raloxifene to not be cost-effective raloxifene 
costs would have to increase 5.7 times or the probability of developing cataracts or 
requiring hysterectomy when on tamoxifen therapy would have to reduce to zero and 
by 21 times respectively. CONCLUSIONS: Raloxifene was found to be cost effective 
compared to tamoxifen in the target population due to its more favourable adverse 
effect proﬁle, despite both drugs having similar efﬁcacy in the chemoprevention of 
breast cancer.
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SYSTEM PERSPECTIVE
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OBJECTIVES: Elaborate an economic evaluation based in a cost-effectiveness model 
to compare sunitinib versus interferon-α (IFNα) and bevacizumab + IFNα as ﬁrst line 
therapy for metastatic renal clear cell carcinoma, in Brazilian Private Health System 
perspective. METHODS: A Markov model, with 6 weeks cycles and a 2-year time 
horizon was developed in Microsoft Excel to evaluate the cost-effectiveness of suni-
tinib vs. IFNα and bevacizumab + IFNα, considering resources from the Brazilian 
Private Health Care. The model considered that the patients received active treatment 
until drug fail. After progression conﬁrmation, patients were treated with a second 
line of active treatment or best supportive care (progression monitoring and palliative 
treatment). Results were expressed as life-years (LY) gained, progression-free LY 
(PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) 
RESULTS: In comparison with IFNα, sunitinib increases LY and PFLY by 0.08 and 
0.33 years respectively, with ICER of R$324,172 (US$190,689 Purchasing Power 
Parity 2009, 1US$ = 1,7R$). In comparison with bevacizumab + IFNα, sunitinib was 
dominant as both more effective (with 0.04 LY and 0.09 PFLY gained) and less costly, 
with a negative ICER of R$ 2,169,212 (US$ 1,549,437) over 2 years, meaning a cost 
saving of R$ 2,169,212 over the combination therapy. CONCLUSIONS: This model 
suggests that when taking the perspective of the Brazilian Private Health Care System 
, sunitinib achieved overall cost saving with improved survival when compared with 
bevacizumab + IFNα in a 2 years time horizon. In comparison to IFNα, sunitinib 
promoted better results on efﬁcacy parameters, with an incremental cost in the same 
time horizon.
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OBJECTIVES: The main objective was to assess cost-effectiveness of multimodal 
screening for ovarian cancer (Annual screening with CA125 marker, followed by 
transvaginal ultrasound for those at increased risk according to CA125 level) from the 
US societal perspective. The secondary objective was to facilitate an economic compari-
son between two different screening strategies (multimodal screening and ultrasound 
screening), which have been proven to be effective in improving early detection of 
ovarian cancer. METHODS: A lifetime incremental cost-effectiveness model was con-
structed to calculate the increase of costs, and QALYs gained by the multimodal screen-
ing. In this ‘backward induction’ model, the expected costs and outcomes for each 
5-year time-interval are incorporated in subsequent 5-year time period calculations 
over the patient’s entire lifetime. The sensitivity and speciﬁcity of screening, and the 
stage distribution of detected ovarian cancer by the screening were obtained from the 
NCT00058032 clinical trial. The model used a 3% discount rate and reported results 
in 2009 US dollars. RESULTS: Over a lifetime, multimodal screening was estimated to 
cost an additional $820 with an expected gain of 0.0037 quality adjusted life years 
(QALY) or an incremental cost-effectiveness ratio (ICER) of $221,622/ QALY com-
pared to no screening for age 65–69 postmenopausal females. Compared with annual 
transvaginal ultrasound (TVU) screening, multimodal screening improves cost-effec-
tiveness by avoiding unnecessary TVU and surgery, which are risky to the patient and 
costly to the health care system. Cancer incidence rates and time required for screening 
exhibited substantial impact on the model from sensitivity analyses. CONCLUSIONS: 
Multimodal screening is not clearly cost-effective, compared to commonly accepted 
willingness-to-pay thresholds in oncology ($120,000–$150,000/QALY). If high risk 
women were selected for multimodal screening or if the screening was administered as 
part of another medical ofﬁce visit in order to decrease the time required for screening 
test, the ICER could be lower than $120,000/QALY.
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OBJECTIVES: We conducted an economic evaluation with cost and outcome data 
from a randomized controlled trial of promotora led interventions to increase cervical 
cancer screening among three populations of low income Hispanic women. 
METHODS: Hispanic women of Mexican origin, age 21 to 65, with no previous 
cervical cancer, no hysterectomy, and no Pap test within the last 3 years from El Paso, 
Houston, TX and Yakima Valley, WA were randomly assigned to four intervention 
arms, control, video, ﬂip chart, and full (combination of video and ﬂip chart) interven-
tion. Micro costing, including recruitment cost, from both payer and client perspec-
tives were used to estimate intervention costs. Effectiveness measures were the 
prevalence of a self-reported pap test within 6 months after the intervention, analyzed 
under the condition of intention- to- treat. Incremental cost effectiveness ratios 
(ICERs) were the incremental cost per additional women screened. Uncertainty was 
examined with sensitivity analyses. RESULTS: The total cost per participant, was 
$216 for video, $219 for ﬂip chart, and $223 in the full intervention. The proportion 
of women reporting a Pap test was 0.261 in the control arm, 0.484 in the video arm, 
0.515 in the ﬂipchart arm and 0.568 in the full intervention arm. The ICERs were 
$968 comparing the control arm to the movie, $94 comparing the movie to ﬂip chart 
arm and $72 comparing ﬂip chart to the full intervention arm. CONCLUSIONS: The 
promotora led full interventions had important and statistically signiﬁcant effects on 
screening behavior and compare favorably with the other two strategies designed to 
promote cervical cancer screening in the study. The study provides economic informa-
tion for health educators in designing and budgeting promotora based cancer screening 
promotion programs for low income Hispanic women.
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OBJECTIVES: To assess the cost-effectiveness of an EGFR mutation testing strategy 
when considering 1st-line therapy of aNSCLC with geﬁtinib for mutation positive and 
carboplatin-paclitaxel (CP) for mutation negative disease. METHODS: A Discrete 
Event Simulation (DES) was designed to emulate two strategies for treating patients 
with aNSCLC. In the ﬁrst strategy, patients were tested for EGFR genetic mutation 
and given geﬁtinib if positive and CP if negative. In the second strategy patients were 
not tested for genetic mutation and all of them received CP treatment. Probabilities 
for adverse events and progression-free survival (PFS) were obtained from the IPASS 
clinical study (Mok et al 2009). The mutation rate used was 13% and a sensitivity 
analysis was run over this variable. A Markov model using micro simulation was also 
built to compare results of the DES model and assure internal validity. Both models 
were run 10 times with 1000 patients for each strategy. Cost-effectiveness ratios were 
obtained for the testing and not-testing strategies and particularly for positive tested 
patients treated with geﬁtinib. RESULTS: Mean PFS (generated by DES) of tested 
patients with mutation positive disease treated with geﬁtinib was 11.51 (95% CI, 
11.10–11.92) months. PFS of patients who where tested for EGFR mutation (positive 
and negative) was 7.57 (95% CI, 7.50–7.64) months. Patients in the second strategy 
(without testing) yielded 7.11(95% CI, 7.05–7.17) progression-free months. Incremen-
tal cost-effectiveness ratio (ICER) of the testing strategy (including test cost) over the 
not-testing strategy was $1379.49 (95% IC, $1102.10–$1656.88) per progression-free 
month. CONCLUSIONS: According to this analysis, testing aNSCLC patients for 
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EGFR mutation is cost-effective with a willingness to pay above $1379.49 per extra 
progression-free month. In the testing strategy, patients with mutation positive disease 
treated with geﬁtinib beneﬁted from an extra 4.52 progression-free months compared 
to positive patients in the non-testing strategy.
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OBJECTIVES: To utilize data on a large population-based cohort of elderly non-
Hodgkin’s lymphoma (NHL) patients treated with chemotherapy to measure the 
cost-effectiveness (as measured as cost per life-year saved) of white blood cell growth 
factor (CSF) use in a real-world setting METHODS: We identiﬁed 13,203 NHL 
patients from the SEER-Medicare database diagnosed from 1992 to 2002 who 
received chemotherapy within 12 months of diagnosis. Patients were followed from 
initial chemotherapy date until death or end of study period (October 31, 2006). 
Effectiveness of CSF use (primary and secondary prophylaxis) was measured as 
improved overall survival. Costs were estimated by summing reimbursement amounts 
derived from claims. Cost-effectiveness was estimated by modeling the joint inﬂuence 
of CSF use on costs and effectiveness using a propensity-score net monetary beneﬁt 
approach. RESULTS: Primary prophylactic CSF use was cost-effective at lower will-
ingness to pay thresholds, whereas at higher thresholds, not providing prophylactic 
CSF became the cost-effective strategy. For secondary prophylactic CSF use following 
neutropenia, fever, and/or infection, the opposite trend was observed. For low willing-
ness to pay thresholds (less than $20,000 per life year gained), not administering CSF 
was the cost-effective strategy, while CSF use became cost-effective as willingness to 
pay increased (from $100,000+ per life year gained). CONCLUSIONS: To our knowl-
edge this is the ﬁrst population-based study to empirically measure the cost-effective-
ness of CSF among cancer patients treated with chemotherapy. Results suggest that 
CSF use as primary or secondary prophylaxis may be cost-effective depending on 
society’s willingness to pay for improvements in outcomes.
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OBJECTIVES: Erlotinib (Tarceva®) is the ﬁrst and only oral targeted therapy with 
both proven survival and symptom beneﬁt in 2nd and 3rd-line treatment of patients 
with IIIb/IV metastatic NSCLC. We evaluated the cost-effectiveness of erlotinib versus 
pemetrexed, from the National Health Insurance House (NHIH) perspective. 
METHODS: A Markov model was developed using published results from two ran-
domized clinical trials (BR.21 study and Phase III pemetrexed vs. docetaxel) evaluating 
progression-free survival (PFS) and overall survival (OS) in patients with NSCLC. 
Rates of disease progression were modeled using Kaplan-Meier analysis over 24 
months; OS was further extrapolated to 36 months using a Weibull parametric func-
tion. Key assumption in the model was that PFS and OS are similar, due to lack of 
direct comparison studies. Utility values for the PF and progressed health states were 
derived from a utility study conducted in the UK. Direct medical costs were included. 
Resources were estimated using expert opinion from 4 oncology centers. Unit costs 
(for 2009) were derived from Romanian retail prices for drugs, diagnostic and moni-
toring tests and procedures, hospitalizations and post-treatment costs. Costs and 
outcomes were discounted by 3.5%. Sensitivity analysis was performed. RESULTS: 
The total cost per patient treated with erlotinib (47,762 Rol) is much lower than 
pemetrexed cost (76,322 Rol) due to lower drug cost, lower adverse events costs, as 
well as avoidance of administration costs of drug. Analysis showed that although 
clinical beneﬁt is assumed to be the same, there are on average 28,561 Rol saved per 
patient treated with erlotinib instead of pemetrexed. Sensitivity analysis showed that 
even in case of lowering pemetrexed drug cost by 27% (∼two administrations free), 
erlotinib remains a cost-saving therapy. CONCLUSIONS: This study demonstrates 
that erlotinib is a dominant treatment strategy when compared to pemetrexed, allow-
ing for important savings.
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OBJECTIVES: To estimate the probability that epoetin alfa is more cost-effective than 
darbepoetin alfa for the treatment of chemotherapy related anemia in Sweden using 
a cost-effectiveness simulation model. METHODS: Studies for recommended dosing 
regimens of epoetin alfa and darbepoetin alfa were identiﬁed from the literature and 
used to assess haematopoietic response rates, dose escalation rates and the mean 
number of RBC transfusions required in chemotherapy patients. A simulation model 
including estimates of proportions, means and variances of these outcomes was estab-
lished to estimate costs and effectiveness of these agents over 12 weeks. Published 
Swedish unit costs were used. Haematopoietic response rates, deﬁned as Hb level 
≥12 g/dl or an increase from baseline of ≥2 g/dl without a history of transfusion 28 
days prior to response, were used as the effectiveness measure.The probability of 
epoetin alfa exhibiting economic dominance (higher effectiveness and lower cost) and 
also being more cost-effective than darbepoetin alfa was estimated. Six separate sen-
sitivity analyses were conducted where differet costs items, variances/correlations and 
etsimted response rates was tested. RESULTS: According to this model, epoetin alfa 
is associated with greater effectiveness than darbepoetin alfa. Mean haematopoietic 
response rate was 49.86% for epoeting alfa compared to 41.38% in darbepoetin alfa. 
Epoetin alfa is also associated with lower costs than darbepoetin alfa, Sek 31,661 
compared to Sek 43,369 over 12 weeks of therapy. The probability that epoetin alfa 
exhibits economic dominance over darbepoetin alfa is estimated at 92.9% and the 
probability that epoetin alfa is more cost-effective is estimated at 99.9%. Sensitivity 
analyses suggest that the model is robust and, within the margins of uncertainty, not 
sensitive to modiﬁcations in the underlying estimates. CONCLUSIONS: This analysis 
suggests that epoetin alfa should be considered ﬁrst for treating chemotherapy-related 
anaemia given its cost-effectiveness proﬁle. Comparative efﬁcacy of these agents 
should be further assessed in future head-to-head studies.
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REVIEW OF COST-EFFECTIVENESS STUDIES ON AROMATASE 
INHIBITORS FOR THE TREATMENT OF EARLY-STAGE BREAST CANCER
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OBJECTIVES: With the recent updates of clinical guidelines of the National Compre-
hensive Cancer Network (NCCN) and the American Society of Clinical Oncology 
(ASCO), aromatase inhibitors have been included in the management of early-stage 
breast cancer. There has been a great interest to understand the cost-effectiveness of 
this new alternative therapy which is becoming an “optimal therapy” for breast 
cancer. The objective of this study is to review the cost-utility studies on aromatase 
inhibitors for the treatment of early-stage breast cancer and compare reported incre-
mental cost-effectiveness ratios (ICERs). METHODS: We conducted a literature for 
cost-utility studies on anastrazole, letrozole and exemestane. We reviewed the papers 
to extract the information on intervention, comparator, ICER, country, perspective, 
time horizon and clinical data used. For the comparison of reported ICERs, we con-
verted all currencies to US dollars by exchange rate for the cost-year used, then inﬂated 
the values to 2008. RESULTS: A total of 20 papers were identiﬁed (8 on anastrazole, 
8 on letrozole and 4 on exemestane). All studies were from health care perspective 
and sponsored by manufacturers. The time horizon modeled ranged from 7.5 years 
to lifetime, however majority of the studies modeled lifetime. The studies were from 
EU countries and North America such as US, Canada, Belgium, Italy, Sweden and 
UK. The mean ICER values were $24,932 for anastrazole, $21,113 for letrozole and 
$21,428 for exemestane. CONCLUSIONS: The mean ICERs for all three aromatase 
inhibitors are below $25,000; hence they appear to be cost-effective compared to 
tamoxifen therapy for the treatment of early-stage breast cancer.
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OBJECTIVES: Controversy exists regarding the clinical and economic value of pros-
tate cancer (PCa) screening. Our objective is to summarize cost-effectiveness studies 
on Pca screening with PSA. METHODS: We systematically searched the English-
language literature for cost-effectiveness analyses (CEA) on PSA screening programs 
published between 1994–2009 using Medline and other databases. We collected data 
related to methods, screening population, screening strategies, and reporting of results. 
RESULTS: We identiﬁed 10 CEA in PCa screening using PSA, 30% of the studies 
investigated efﬁcacy of PSA on PCa detection, and 70% for efﬁcacy of PSA on both 
PCa detection and consequent treatments. All studies were based on either decision 
tree (60%) or Markov models (40%). Majority of studies only modeled single-episode 
screening (80%). The screening population included men age 40–79 years old, high 
PCa risk sample, or Medicare population. Four types of screening strategies were 
compared: 1) no screening vs. PSA, or PSA combined with digital rectal examination 
(DRE); 2) different thresholds of normal PSA; 3) isoforms of PSA (PSA, free PSA, 
complexed PSA); 4) different screening intervals. Method of cost-effectiveness 
measures varied from studies. Outcomes were presented as costs/quality adjusted life 
years (QALY) (30%), costs/life-years saved (40%), costs/curable cancers (20%), costs/
detected cancer (10%). Only ﬁve studies originated in U.S. As compared to no screen-
ing, four studies reported an incremental cost-effectiveness ratio for screening with 
PSA or combined with DRE that ranged from $12,502 to $65,909/life-year saved in 
Medicare population aged 65–69 years, and general population aged 70–79 years, 
respectively. One study reported that PSA- alone screening was dominated by no 
screening in the general population aged 50–79 years. CONCLUSIONS: Economic 
evaluation of PSA in Pca screening remains limited. Cost-effectiveness ratios reported 
from studies varied from screening populations, calendar year, and country original, 
which made the comparisons difﬁcult.
